Article History
Received: 16 December 2021
Accepted: 9 March 2022
First Online: 13 April 2022
Declarations
:
: Joshua Holmes has no conflicts of interest. Liam Heaney is the Academic Lead for the UK MRC Consortium for Stratified Medicine in Severe Asthma—Industrial Pharma partners Amgen, AstraZeneca, Medimmune, Janssen, Novartis, Roche/Genentech, GlaxoSmithKline and Boehringer Ingelheim; prior project grant funding from Medimmune, Novartis UK, Roche/Genentech and GlaxoSmithKline; has taken part in Advisory Boards/Lectures supported by Chiesi, Novartis, Roche/Genentech, GlaxoSmithKline, Teva, Theravance and Vectura; has travel funding support to international respiratory meetings (AstraZeneca, Chiesi, Novartis, Boehringer Ingelheim, Teva and GlaxoSmithKline) and has taken part in asthma clinical trials (GlaxoSmithKline, Schering Plough, Synairgen, Novartis and Roche/Genentech) for which his institution was remunerated. Lorcan McGarvey reports personal fees from GSK, grants and personal fees from MERCK, personal fees from Shionogi, Bayer, Bellus Health and Nocion, grants and personal fees from Chiesi and personal fees from Applied Clinical Intelligence, outside the submitted work.